LY2605541
Phase 3Biologic
Eli LillyLY2605541 is one of 132 biologic programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
5
Indications
17
Total Trials
0
Active Trials
131
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1LY2605541
Eli LillyPhase 3
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Routine Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 1 Diabetes3 trials
Type 2 Diabetes Mellitus3 trials
ART2 trials
Type 2 Diabetes2 trials
5 more indications
Type 1 Diabetic1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY2605541. EMBL-EBI & Wellcome Sanger Institute.
- [4]